Ignite Creation Date:
2025-12-25 @ 1:45 AM
Ignite Modification Date:
2026-02-28 @ 12:03 AM
Study NCT ID:
NCT00556894
Status:
COMPLETED
Last Update Posted:
2018-03-29
First Post:
2007-11-08
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'removedCountries': ['Serbia and Montenegro']}, 'conditionBrowseModule': {'meshes': [{'id': 'D001172', 'term': 'Arthritis, Rheumatoid'}], 'ancestors': [{'id': 'D001168', 'term': 'Arthritis'}, {'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D012216', 'term': 'Rheumatic Diseases'}, {'id': 'D003240', 'term': 'Connective Tissue Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C478920', 'term': 'CF101'}, {'id': 'C084956', 'term': "N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine"}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'pnina@canfite.co.il', 'phone': '011972 39241114', 'title': 'Pnina Fishman, PhD', 'organization': 'Can-Fite Biopharma'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': False}}, 'adverseEventsModule': {'eventGroups': [{'id': 'EG000', 'title': 'CF101 0.1mg', 'description': 'CF101 0.1mg q12 for 12 weeks', 'otherNumAtRisk': 82, 'otherNumAffected': 2, 'seriousNumAtRisk': 82, 'seriousNumAffected': 3}, {'id': 'EG001', 'title': 'CF101 1mg', 'description': 'CF101 1mg q12 for 12 weeks', 'otherNumAtRisk': 87, 'otherNumAffected': 5, 'seriousNumAtRisk': 87, 'seriousNumAffected': 2}, {'id': 'EG002', 'title': 'Placebo', 'description': 'Matching Placebo q12 for 12 weeks', 'otherNumAtRisk': 84, 'otherNumAffected': 1, 'seriousNumAtRisk': 84, 'seriousNumAffected': 3}], 'otherEvents': [{'term': 'Nausea', 'notes': 'Nausea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 82, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 87, 'numAffected': 5}, {'groupId': 'EG002', 'numAtRisk': 84, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders'}], 'seriousEvents': [{'term': 'Pancytopenia', 'notes': 'Pancytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 82, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 87, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 84, 'numAffected': 0}], 'organSystem': 'Blood and lymphatic system disorders'}, {'term': 'Microcytic anemia', 'notes': 'HYPOCHROMIC MICROCYTIC ANEMIA III ST.', 'stats': [{'groupId': 'EG000', 'numAtRisk': 82, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 87, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 84, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders'}, {'term': 'Alanine aminotransferase and Aspartate aminotransferase increased', 'notes': 'Elevated ALAT and ASAT', 'stats': [{'groupId': 'EG000', 'numAtRisk': 82, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 87, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 84, 'numAffected': 1}], 'organSystem': 'Investigations'}, {'term': 'Eyelid oedema', 'notes': 'OEDEMA OF BOTH EYELIDS WITH CARIAL RASH ON THE NECK', 'stats': [{'groupId': 'EG000', 'numAtRisk': 82, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 87, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 84, 'numAffected': 1}], 'organSystem': 'Eye disorders'}, {'term': 'Nausea and Diarrhoea', 'notes': 'Nausea and Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 82, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 87, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 84, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'ACR20 at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '66', 'groupId': 'OG000'}, {'value': '68', 'groupId': 'OG001'}, {'value': '65', 'groupId': 'OG002'}]}], 'groups': [{'id': 'OG000', 'title': 'CF101 0.1mg', 'description': 'CF101 0.1mg orally q12'}, {'id': 'OG001', 'title': 'CF101 1mg', 'description': 'CF101 1mg orally q12'}, {'id': 'OG002', 'title': 'Placebo', 'description': 'Placebo orally q12'}], 'classes': [{'categories': [{'measurements': [{'value': '29', 'groupId': 'OG000'}, {'value': '34', 'groupId': 'OG001'}, {'value': '33', 'groupId': 'OG002'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '12 weeks', 'description': 'Number of patients that achieved 20% response at week 12 in American College of Rheumatology Criteria', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'ACR 20/50/70, ITT and Evaluable Population, Last Observation Carried Disease Activity Score (DAS28) Change From Baseline at Each Visit in the Efficacy Parameters', 'timeFrame': '12 weeks', 'description': 'ACR20/50/70 responses over time (intent-to-treat \\[ITT\\], last observation carried forward \\[LOCF\\]), mean changes in individual components of the ACR response criteria, DAS28, European League Against Rheumatism (EULAR) responses', 'reportingStatus': 'NOT_POSTED', 'denomUnitsSelected': 'Participants'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'CF101 0.1mg', 'description': 'CF101 0.1mg orally q12 for 12 weeks'}, {'id': 'FG001', 'title': 'CF101 1mg', 'description': 'CF101 1mg orally q12 for 12 weeks'}, {'id': 'FG002', 'title': 'Placebo', 'description': 'Matching placebo'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '82'}, {'groupId': 'FG001', 'numSubjects': '87'}, {'groupId': 'FG002', 'numSubjects': '84'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '66'}, {'groupId': 'FG001', 'numSubjects': '68'}, {'groupId': 'FG002', 'numSubjects': '65'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '16'}, {'groupId': 'FG001', 'numSubjects': '19'}, {'groupId': 'FG002', 'numSubjects': '19'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '3'}, {'groupId': 'FG002', 'numSubjects': '3'}]}, {'type': 'Death', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '0'}, {'groupId': 'FG002', 'numSubjects': '0'}]}, {'type': 'regulatory decision in Bulgaria', 'reasons': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '14'}, {'groupId': 'FG002', 'numSubjects': '13'}]}, {'type': 'Change in therapy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '2'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '1'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '82', 'groupId': 'BG000'}, {'value': '87', 'groupId': 'BG001'}, {'value': '84', 'groupId': 'BG002'}, {'value': '253', 'groupId': 'BG003'}]}], 'groups': [{'id': 'BG000', 'title': 'CF101 0.1mg', 'description': 'CF101: orally q12h'}, {'id': 'BG001', 'title': 'CF101 1mg', 'description': 'CF101: orally q12h'}, {'id': 'BG002', 'title': 'Placebo', 'description': 'CF101: orally q12h'}, {'id': 'BG003', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '66', 'groupId': 'BG000'}, {'value': '69', 'groupId': 'BG001'}, {'value': '69', 'groupId': 'BG002'}, {'value': '204', 'groupId': 'BG003'}]}, {'title': '>=65 years', 'measurements': [{'value': '16', 'groupId': 'BG000'}, {'value': '18', 'groupId': 'BG001'}, {'value': '15', 'groupId': 'BG002'}, {'value': '49', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '55', 'groupId': 'BG000', 'lowerLimit': '24', 'upperLimit': '75'}, {'value': '54', 'groupId': 'BG001', 'lowerLimit': '25', 'upperLimit': '75'}, {'value': '54', 'groupId': 'BG002', 'lowerLimit': '33', 'upperLimit': '73'}, {'value': '54', 'groupId': 'BG003', 'lowerLimit': '24', 'upperLimit': '75'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'years', 'dispersionType': 'FULL_RANGE'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '68', 'groupId': 'BG000'}, {'value': '64', 'groupId': 'BG001'}, {'value': '71', 'groupId': 'BG002'}, {'value': '203', 'groupId': 'BG003'}]}, {'title': 'Male', 'measurements': [{'value': '14', 'groupId': 'BG000'}, {'value': '23', 'groupId': 'BG001'}, {'value': '13', 'groupId': 'BG002'}, {'value': '50', 'groupId': 'BG003'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'Serbia', 'categories': [{'measurements': [{'value': '22', 'groupId': 'BG000'}, {'value': '20', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}, {'value': '62', 'groupId': 'BG003'}]}]}, {'title': 'Ukraine', 'categories': [{'measurements': [{'value': '22', 'groupId': 'BG000'}, {'value': '26', 'groupId': 'BG001'}, {'value': '26', 'groupId': 'BG002'}, {'value': '74', 'groupId': 'BG003'}]}]}, {'title': 'Israel', 'categories': [{'measurements': [{'value': '9', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '26', 'groupId': 'BG003'}]}]}, {'title': 'Bulgaria', 'categories': [{'measurements': [{'value': '29', 'groupId': 'BG000'}, {'value': '32', 'groupId': 'BG001'}, {'value': '30', 'groupId': 'BG002'}, {'value': '91', 'groupId': 'BG003'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 253}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2008-02'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2011-08', 'dispFirstSubmitDate': '2011-06-14', 'completionDateStruct': {'date': '2009-04', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2018-02-27', 'studyFirstSubmitDate': '2007-11-08', 'dispFirstSubmitQcDate': '2011-06-30', 'resultsFirstSubmitDate': '2015-02-24', 'studyFirstSubmitQcDate': '2007-11-09', 'dispFirstPostDateStruct': {'date': '2011-07-01', 'type': 'ESTIMATED'}, 'lastUpdatePostDateStruct': {'date': '2018-03-29', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2015-02-24', 'studyFirstPostDateStruct': {'date': '2007-11-12', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2015-03-09', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2009-03', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'ACR20 at Week 12', 'timeFrame': '12 weeks', 'description': 'Number of patients that achieved 20% response at week 12 in American College of Rheumatology Criteria'}], 'secondaryOutcomes': [{'measure': 'ACR 20/50/70, ITT and Evaluable Population, Last Observation Carried Disease Activity Score (DAS28) Change From Baseline at Each Visit in the Efficacy Parameters', 'timeFrame': '12 weeks', 'description': 'ACR20/50/70 responses over time (intent-to-treat \\[ITT\\], last observation carried forward \\[LOCF\\]), mean changes in individual components of the ACR response criteria, DAS28, European League Against Rheumatism (EULAR) responses'}]}, 'oversightModule': {'oversightHasDmc': False}, 'conditionsModule': {'conditions': ['Rheumatoid Arthritis']}, 'descriptionModule': {'briefSummary': 'This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking methotrexate for at least 6 months.', 'detailedDescription': 'This will be a multi-center, randomized, double-blind, parallel-group, placebo-controlled, dose-finding study in which patients with active RA despite receiving methotrexate for at least 6 months (at unchanged doses for \\>=2 months) will be randomized to the addition of either CF101 0.1 mg, CF101 1 mg, or placebo given orally q12h for 12 weeks. Screening examinations will occur within 1 month prior to dosing. Washout of other disease-modifying antirheumatic drugs (DMARDs) (with the exception of hydroxychloroquine), including biological agents, will occur prior to dosing; if washout is necessary, patients must re-qualify for inclusion following the washout. Doses of nonsteroidal anti-inflammatory drugs (NSAIDS) and corticosteroids must be stable for \\>=1 month prior to dosing and remain so during protocol participation. Disease activity will be assessed using swollen and tender joint counts, physician and patient global assessments (by visual analog scale, VAS), patient reported pain (by VAS), a Health Assessment Questionnaire (HAQ) Disability Index (DI), Westergren erythrocyte sedimentation rate (ESR, Screening, Weeks 0 and12), and C-reactive protein (CRP) levels. Assessments will take place at Screening, Baseline (Week 0), and at Weeks 2, 4, 8, and 12.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '75 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Males and females ages 18-75 years\n* Meet the criteria of the American College of Rheumatology for RA (Arnett FC et al. Arthritis Rheum 1988;31:315-324; refer to Appendix 1. diagnostic criteria for Rheumatoid Arthritis)\n* Not bed- or wheelchair-bound\n* Active RA, as indicated by the presence of (a) \\>=6 swollen joints (28 joint count); AND (b) \\>=6 tender joints (28 joint count); AND either: (c) Westergren ESR of \\>=28 mm/hour; OR (d) CRP level above the upper limit of normal for the central reference laboratory\n* Treatment with weekly oral or parenteral methotrexate for \\>=6 months prior to baseline\n* Methotrexate route of administration has been unchanged for \\>=2 months prior to baseline\n* Dose of methotrexate has been stable at 15-25 mg/week for \\>=2 months, and is expected to remain stable throughout the study; the stable dose of methotrexate may alternatively be 10-12.5 mg/week if documented toxicity has precluded a higher dose\n* If taking hydroxychloroquine or chloroquine, administration duration has been for \\>=3 months and dose has been stable for \\>=2 months prior to baseline\n* If taking a nonsteroidal anti-inflammatory agent (NSAID), dose has been stable for at least 1 month prior to baseline, and will remain unchanged during protocol participation\n* If taking an oral corticosteroid, dose is \\<10 mg/day prednisone or equivalent, has been stable for at least 1 month prior to the stabilization period, and will remain stable through the stabilization and entire treatment and follow-up period\n* Negative screening serum pregnancy test for female patients of childbearing potential\n* Females of childbearing potential must utilize, throughout the course of the trial, 2 methods of contraception deemed adequate by the Investigator (for example, oral contraceptive pills plus a barrier method)\n\nExclusion Criteria:\n\n* Receipt of any of the following for at least a 1 month stabilization period prior to dosing: sulfasalazine, oral or injectable gold, azathioprine, minocycline, penicillamine, anakinra\n* Receipt of etanercept for at least a 6 week period prior to dosing\n* Receipt of cyclosporine, infliximab or adalimumab for at least a 2 month period prior to dosing\n* Receipt of leflunomide for at least a 2 month period prior to screening, unless patient has undergone cholestyramine washout at least 1 month prior to dosing\n* Receipt of cyclophosphamide for at least a 6 month period prior to dosing\n* Receipt of rituximab at any previous time\n* Participation in a previous trial CF101 trial\n* Use of oral corticosteroids \\>10 mg of prednisone, or equivalent, per day\n* Change in NSAID dose level for 1 month prior to dosing\n* Change in oral corticosteroid dose level during the 1 month prior to, or during, the stabilization period vChange in hydroxychloroquine or chloroquine dose level during the 2 months prior to, or during, the stabilization period\n* Receipt of parenteral or intra-articular corticosteroids during the 1 month prior to, or during, the stabilization period\n* Significant cardiac arrhythmia or conduction block, congestive heart failure, or any other evidence of clinically significant heart disease; other clinically significant findings on screening electrocardiogram (ECG)\n* Hemoglobin level \\<9.0 gm/dL at the screening visit\n* Platelet count \\<125,000/mm3 at the screening visit\n* White blood cell count \\<3000/mm3 at the screening visit\n* Serum creatinine level outside the central laboratory's normal limits at the screening visit\n* Liver aminotransferase (ALT and/or AST) levels greater than 1.25 times the central laboratory's upper limit of normal at the screening visit\n* Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study"}, 'identificationModule': {'nctId': 'NCT00556894', 'briefTitle': 'Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients', 'organization': {'class': 'INDUSTRY', 'fullName': 'Can-Fite BioPharma'}, 'officialTitle': 'A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis', 'orgStudyIdInfo': {'id': 'CF101-203RA'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'CF101 0.1 mg', 'description': 'CF101 0.1 mg was given orally q12h', 'interventionNames': ['Drug: CF101']}, {'type': 'EXPERIMENTAL', 'label': 'CF101 1 mg', 'description': 'CF101 1 mg was given orally q12h', 'interventionNames': ['Drug: CF101']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Matched placebo was given orally q12h', 'interventionNames': ['Drug: Placebo']}], 'interventions': [{'name': 'CF101', 'type': 'DRUG', 'otherNames': ['IB-MECA'], 'description': 'orally q12h', 'armGroupLabels': ['CF101 0.1 mg', 'CF101 1 mg']}, {'name': 'Placebo', 'type': 'DRUG', 'description': 'orally q12h', 'armGroupLabels': ['Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '4002', 'city': 'Plovdiv', 'country': 'Bulgaria', 'facility': "Clinic of Rheumatology at MHAT 'Sveti Georgi'", 'geoPoint': {'lat': 42.15387, 'lon': 24.75001}}, {'zip': '1612', 'city': 'Sofia', 'country': 'Bulgaria', 'facility': "Clinic of Rheumatology at MHAT 'Sveti Ivan Rilski'", 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'city': 'Sofia', 'country': 'Bulgaria', 'facility': "Clinic of internal diseases at NMTH 'Tzar Boris Treti'", 'geoPoint': {'lat': 42.69751, 'lon': 23.32415}}, {'zip': '6000', 'city': 'Stara Zagora', 'country': 'Bulgaria', 'facility': "Second Clinic of Internal Diseases at MHAT 'Stara Zagora'", 'geoPoint': {'lat': 42.43205, 'lon': 25.64262}}, {'zip': '9010', 'city': 'Varna', 'country': 'Bulgaria', 'facility': "Clinic of Rheumatology at MHAT 'Sveta Marina' - Varna", 'geoPoint': {'lat': 43.21912, 'lon': 27.91024}}, {'zip': '50005', 'city': 'Hradec Králové', 'country': 'Czechia', 'facility': 'University Hospital Hradec Kralove', 'geoPoint': {'lat': 50.20923, 'lon': 15.83277}}, {'zip': '12850', 'city': 'Prague', 'country': 'Czechia', 'facility': 'Institute of Rheumatology', 'geoPoint': {'lat': 50.08804, 'lon': 14.42076}}, {'zip': '76001', 'city': 'Zlín', 'country': 'Czechia', 'facility': 'Rheumotology Out-patient Clinic', 'geoPoint': {'lat': 49.22645, 'lon': 17.67065}}, {'city': 'Afula', 'country': 'Israel', 'facility': 'Haemek Medical Center', 'geoPoint': {'lat': 32.60907, 'lon': 35.2892}}, {'zip': '78278', 'city': 'Ashkelon', 'country': 'Israel', 'facility': 'Barzilai Medical Center', 'geoPoint': {'lat': 31.66926, 'lon': 34.57149}}, {'zip': '31096', 'city': 'Haifa', 'country': 'Israel', 'facility': 'Rambam Medical Center', 'geoPoint': {'lat': 32.81303, 'lon': 34.99928}}, {'city': 'Jerusalem', 'country': 'Israel', 'facility': 'Hadassah Har-Hazofim Medical Center', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'zip': '44281', 'city': 'Kfar Saba', 'country': 'Israel', 'facility': 'Meir Medical Center', 'geoPoint': {'lat': 32.175, 'lon': 34.90694}}, {'zip': '82300', 'city': 'Elblag', 'country': 'Poland', 'facility': 'Wojewodzki Szpital Zespolony w Elblagu', 'geoPoint': {'lat': 54.1522, 'lon': 19.40884}}, {'zip': '20607', 'city': 'Lublin', 'country': 'Poland', 'facility': 'Niepubliczny Zaklad Opieki Zdrowotnej', 'geoPoint': {'lat': 51.25058, 'lon': 22.57009}}, {'zip': '81967', 'city': 'Sopot', 'country': 'Poland', 'facility': 'Wojewodzki Zespol Reumatologiczny w Sopocie', 'geoPoint': {'lat': 54.4418, 'lon': 18.56003}}, {'zip': '71252', 'city': 'Szczecin', 'country': 'Poland', 'facility': 'Samodzielny Publiczny Szpital Kliniczny Nr 1 P.A.M. w Szczecinie', 'geoPoint': {'lat': 53.42894, 'lon': 14.55302}}, {'zip': '87100', 'city': 'Torun', 'country': 'Poland', 'facility': 'Niepubliczny Zaklad Opieki Zdrowotnej "NASZ LEKARZ"', 'geoPoint': {'lat': 53.01375, 'lon': 18.59814}}, {'zip': '11000', 'city': 'Belgrade', 'country': 'Serbia', 'facility': 'Institute of Rheumatology - Belgrade', 'geoPoint': {'lat': 44.80401, 'lon': 20.46513}}, {'zip': '18205', 'city': 'Niška Banja', 'country': 'Serbia', 'facility': 'Institute for Prevention, Treatment, and Rehabilitation of Rheumatoid and Cardiovascular Diseases Niska Banja', 'geoPoint': {'lat': 43.29507, 'lon': 22.0057}}, {'zip': '83114', 'city': 'Donetsk', 'country': 'Ukraine', 'facility': 'Central Municipal Clinical Hospital nº1', 'geoPoint': {'lat': 48.023, 'lon': 37.80224}}, {'zip': '01023', 'city': 'Kiev', 'country': 'Ukraine', 'facility': 'Kyiv Central Municipal Hospital', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '01103', 'city': 'Kiev', 'country': 'Ukraine', 'facility': 'City Clinical Hospital N12', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '03680', 'city': 'Kiev', 'country': 'Ukraine', 'facility': 'National Scientific Centre of AMS of Ukraine', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '04053', 'city': 'Kiev', 'country': 'Ukraine', 'facility': 'O.O. Bogomolets National Medical University', 'geoPoint': {'lat': 50.45466, 'lon': 30.5238}}, {'zip': '21018', 'city': 'Vinnycia', 'country': 'Ukraine', 'facility': 'Vinnitsya Regional Clinical Hospital'}], 'overallOfficials': [{'name': 'Michael H Silverman, MD', 'role': 'STUDY_DIRECTOR', 'affiliation': 'BioStrategics Consulting Ltd'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Can-Fite BioPharma', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}